Buddy Creech
-
Study finds Moderna’s COVID-19 vaccine safe and effective for young children
A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age. Read MoreNov 4, 2022
-
VUMC-led study finds Moderna COVID vaccine safe and effective for children
Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by C. Buddy Creech, MD, MPH, has found. Read MoreMay 12, 2022
-
36 scholars honored at endowed chair investiture ceremony
Vanderbilt Chancellor Daniel Diermeier and Provost and Vice Chancellor for Academic Affairs C. Cybele Raver honored 36 scholars from across the university at an endowed chair investiture ceremony on campus March 30. Read MoreMar 31, 2022
-
‘NBJ’ honors three from Vanderbilt as 2021 health care innovators
Three Vanderbilt health care leaders—André L. Churchwell, C. Buddy Creech and Consuelo H. Wilkins—have been recognized by the "Nashville Business Journal" with 2021 Health Care Innovation Awards. The awards “honor those who pushed the region’s signature industry forward and helped protect their communities in uncertain times.” Read MoreSep 7, 2021
-
Churchwell, Creech, Wilkins among NBJ award winners
Three leaders of the Vanderbilt University Medical Center community are among the winners of the Nashville Business Journal’s 2021 Health Care Innovation awards. Read MoreAug 19, 2021
-
Dr. Buddy Creech answers first-year students’ COVID-19 questions
Vanderbilt first-year students recently met with Buddy Creech, director of the Vanderbilt Vaccine Research Program and associate professor of pediatrics, for a special virtual chat to answer some of their COVID-19 vaccine questions. Read MoreFeb 15, 2021
-
VUMC begins study of second COVID-19 vaccine
Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Read MoreNov 2, 2020
-
COVID treatment studied by VUMC gains FDA approval
Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19. Read MoreOct 26, 2020
-
Remdesivir helps reduce COVID-19 recovery time: study
The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine. Read MoreJun 4, 2020
-
Buddy Creech, BS’95, MPH’06: Leading COVID-19 treatment trials
Buddy Creech, director, Vanderbilt Vaccine Research Program, is helping lead some of the NIH-funded treatment trials of COVID-19 in hospitalized patients at Vanderbilt University Medical Center. Read MoreMay 15, 2020
-
Team seeks to identify immune response to influenza
Vanderbilt researchers led by Buddy Creech are searching for the key to lasting protection against influenza by examining naturally protecting cells found in bone marrow. Read MoreNov 1, 2018
-
Volunteers sought for bird flu vaccine trial
Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.” Read MoreMar 15, 2018
-
Vanderbilt leads international effort to develop universal flu vaccine
Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world. Read MoreOct 26, 2017
-
New approach for staph-related skin abscesses explored
New multicenter research that includes Vanderbilt University Medical Center (VUMC) investigators, could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria. Read MoreJul 13, 2017
-
Study tests shorter antibiotic course in children
Researchers at Vanderbilt University Medical Center (VUMC) are leading a multicenter clinical trial to evaluate whether a shorter course of antibiotics — five days instead of 10 — is effective at treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of taking antibiotics. Read MoreDec 1, 2016
-
NIH launches website for StoryCorps project
The National Institutes of Health (NIH) is launching its Voices of the NIH Community website, which features a collection of StoryCorps audio recordings from patients, families, researchers, doctors, nurses, staff and volunteers in both the NIH and Vanderbilt University Medical Center (VUMC) communities. Read MoreJul 28, 2016
-
Creech to direct Vanderbilt Vaccine Research Program
Buddy Creech, M.D., MPH, associate professor of Pediatrics, has been named director of the Vanderbilt Vaccine Research Program (VVRP) in the Division of Pediatric Infectious Diseases. Read MoreOct 8, 2015
-
Faculty Senate introduces leaders; newsletter to launch in October
The Faculty Senate, the representative and deliberative body of the Vanderbilt faculties, introduces its leadership for 2015-16. Read MoreSep 16, 2015
-
Faculty Senate meeting minutes for March 2015 available online
Minutes from the Vanderbilt Faculty Senate’s March 12 meeting are now available online on the Faculty Senate website. Read MoreMay 1, 2015
-
Staph ‘gangs’ share nutrients during infection: study
Antibiotic-resistant bacteria can share resources to cause chronic infections, Vanderbilt investigators have discovered. The findings shed light on a long-standing question in infectious diseases and may inform new treatment strategies. Read MoreOct 16, 2014